Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography.
Publication/Presentation Date
10-1-1988
Abstract
Transrectal ultrasonography has proved valuable in assessing the effect of primary treatment modalities for prostate carcinoma. This study shows patients who had a significant reduction in primary tumor volume had a significantly better prognosis and had less local symptoms than did the group of patients that did not have a significant reduction (less than 50%) in primary volume secondary to therapy. Patients were treated with either castration or Zoladex and all had Stage D2 cancer of the prostate.
Volume
32
Issue
4
First Page
285
Last Page
287
ISSN
0090-4295
Published In/Presented At
Drago, J. R., Nesbitt, J. A., & Cirulli, C. (1988). Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography. Urology, 32(4), 285–287. https://doi.org/10.1016/0090-4295(88)90227-0
PubMedID
2972104
Department(s)
Department of Surgery
Document Type
Article